11/21/2024

Janusmed kön och genus

Janusmed kön och genus – metoklopramid

Janusmed kön och genus är ett kunskapsstöd som tillhandahåller information om köns- och genusaspekter på läkemedelsbehandling. Kunskapsstödet är avsedd främst för hälso- och sjukvårdspersonal. Texterna är generella och ska inte ses som behandlingsriktlinjer. Det är alltid behandlande läkare som ansvarar för patientens medicinering.

För att komma till startsidan för Janusmed kön och genus och för att göra sökningar klicka här.

Tillbaka till index
A A
A A

Metoklopramid

Metoklopramid

Klass : A

Visa all info

Skriv ut

Kontakta oss

  1. Fass R, Pieniaszek HJ, Thompson JR. Pharmacokinetic comparison of orally-disintegrating metoclopramide with conventional metoclopramide tablet formulation in healthy volunteers. Aliment Pharmacol Ther. 2009;30:301-6.

  2. Primperan (metoclopramide). Summary of Product Characteristics. Swedish Medical Products Agency [updated 2023-03-23, cited 2023-06-12]

  3. Roila F, Tonato M, Basurto C, Canaletti R, Morsia D, Passalacqua R et al. Antiemetic activity of two different high doses of metoclopramide in cisplatin-treated cancer patients: a randomized double-blind trial of the Italian Oncology Group for Clinical Research. Cancer Treat Rep. 1985;69:1353-7.

  4. Tsavaris N, Mylonakis N, Bacoyiannis C, Kosmas C, Kalergis G, Iakovidis V et al. Factors that influence the antiemetic activity of metoclopramide to cisplatin based chemotherapy. Oncol Rep. 1998;5:1147-55.

  5. Kreel L, Trott M, Howells TH. The influence of oral metoclopramide on gastric emptying after a fixed water load. Clin Radiol. 1972;23:213-8.

  6. Bateman DN, Rawlins MD, Simpson JM. Extrapyramidal reactions with metoclopramide. Br Med J (Clin Res Ed). 1985;291:930-2.

  7. Pasricha PJ, Pehlivanov N, Sugumar A, Jankovic J. Drug Insight: from disturbed motility to disordered movement--a review of the clinical benefits and medicolegal risks of metoclopramide. Nat Clin Pract Gastroenterol Hepatol. 2006;3:138-48.

  8. Svendsen K, Wood M, Olsson E, Nordeng H. Reported time to onset of neurological adverse drug reactions among different age and gender groups using metoclopramide: an analysis of the global database Vigibase®. Eur J Clin Pharmacol. 2018;74(5):627-636.

  9. Merrill RM, Lyon JL, Matiaco PM. Tardive and spontaneous dyskinesia incidence in the general population. BMC Psychiatry. 2013;13:152.

  10. Yassa R, Jeste DV. Gender differences in tardive dyskinesia: a critical review of the literature. Schizophr Bull. 1992;18:701-15.

  11. Parkman HP, Mishra A, Jacobs M, Pathikonda M, Sachdeva P, Gaughan J et al. Clinical response and side effects of metoclopramide: associations with clinical, demographic, and pharmacogenetic parameters. J Clin Gastroenterol. 2012;46:494-503.

  12. Statistikdatabas för läkemedel. Stockholm: Socialstyrelsen. 2022 [cited 2023-03-02.]

  1. Fass R, Pieniaszek HJ, Thompson JR. Pharmacokinetic comparison of orally-disintegrating metoclopramide with conventional metoclopramide tablet formulation in healthy volunteers. Aliment Pharmacol Ther. 2009;30:301-6.
  2. Primperan (metoclopramide). Summary of Product Characteristics. Swedish Medical Products Agency [updated 2023-03-23, cited 2023-06-12]
  3. Roila F, Tonato M, Basurto C, Canaletti R, Morsia D, Passalacqua R et al. Antiemetic activity of two different high doses of metoclopramide in cisplatin-treated cancer patients: a randomized double-blind trial of the Italian Oncology Group for Clinical Research. Cancer Treat Rep. 1985;69:1353-7.
  4. Tsavaris N, Mylonakis N, Bacoyiannis C, Kosmas C, Kalergis G, Iakovidis V et al. Factors that influence the antiemetic activity of metoclopramide to cisplatin based chemotherapy. Oncol Rep. 1998;5:1147-55.
  5. Kreel L, Trott M, Howells TH. The influence of oral metoclopramide on gastric emptying after a fixed water load. Clin Radiol. 1972;23:213-8.
  6. Bateman DN, Rawlins MD, Simpson JM. Extrapyramidal reactions with metoclopramide. Br Med J (Clin Res Ed). 1985;291:930-2.
  7. Pasricha PJ, Pehlivanov N, Sugumar A, Jankovic J. Drug Insight: from disturbed motility to disordered movement--a review of the clinical benefits and medicolegal risks of metoclopramide. Nat Clin Pract Gastroenterol Hepatol. 2006;3:138-48.
  8. Svendsen K, Wood M, Olsson E, Nordeng H. Reported time to onset of neurological adverse drug reactions among different age and gender groups using metoclopramide: an analysis of the global database Vigibase®. Eur J Clin Pharmacol. 2018;74(5):627-636.
  9. Merrill RM, Lyon JL, Matiaco PM. Tardive and spontaneous dyskinesia incidence in the general population. BMC Psychiatry. 2013;13:152.
  10. Yassa R, Jeste DV. Gender differences in tardive dyskinesia: a critical review of the literature. Schizophr Bull. 1992;18:701-15.
  11. Parkman HP, Mishra A, Jacobs M, Pathikonda M, Sachdeva P, Gaughan J et al. Clinical response and side effects of metoclopramide: associations with clinical, demographic, and pharmacogenetic parameters. J Clin Gastroenterol. 2012;46:494-503.
  12. Statistikdatabas för läkemedel. Stockholm: Socialstyrelsen. 2022 [cited 2023-03-02.]